Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0.050693339395317 0.050693339395317 0.0456922027733575
Stock impact report

Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK™ (tazemetostat) for the Treatment of Follicular Lymphoma

Epizyme, Inc (EPZM)  More Company Research Source: Business Wire
Last epizyme, inc earnings: 10/30 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: epizyme.com
PDF Approval Would Expand TAZVERIK™ Label into Second IndicationPDUFA Target Action Date Scheduled for June 18, 2020 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for the accelerated approval of TAZVERIK™ (tazemetostat) for patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. The FDA granted Priority Review and has designated the company’s application as a supplemental NDA (sNDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 18, 2020. Priority Review is granted to investigational therapies that, if approved, may offer significant improvements in the treatment, prevention or diagnosis of a serious condition.“Follicular lymphoma is an incurable [Read more]
Impact snapshot Event time: EPZM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
EPZM alerts
from News Quantified
Opt-in for
EPZM alerts

from News Quantified
Opt-in for
EPZM alerts

from News Quantified